Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 11/20 | 0.91 |
| ▸ | MMP13 | P45452 | 10/20 | 0.91 |
| ▸ | MMP2 | P08253 | 1/20 | 0.69 |
| ▸ | MMP9 | P14780 | 1/20 | 0.69 |
| ▸ | MMP14 | P50281 | 1/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.61 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5613747 | 0.96 | MMP12 (1.00) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL8333817 | 0.85 | MMP12 (0.80) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL4745347 | 0.85 | MMP12 (0.80) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL687094 | 0.85 | MMP12 (0.80) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL11823926 | 0.84 | MMP12 (0.67) | MMP12MMP13FFAR1SRD5A2FFAR4 | |
| SCHEMBL5613493 | 0.84 | MMP12 (0.92) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL6460737 | 0.83 | MMP12 (0.65) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL5613354 | 0.82 | MMP12 (1.00) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL5498859 | 0.82 | MMP12 (0.67) | MMP12MMP13MMP2MMP9MMP14 | |
| SCHEMBL10855546 | 0.81 | MMP12 (0.63) | MMP12MMP13MMP2MMP9MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250439-B2 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| US-7250439-B2 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| US-7250439-B2 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-07-31 | — | — | US | disclosed |
| EP-1654213-B1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1654213-B1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| US-20060160875-A1 | Matrix metalloproteinase inhibitors | GLAXO GROUP LIMITED (GB) | 2006-07-20 | — | — | US | disclosed |
| EP-1654213-A1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-05-10 | — | — | EP | disclosed |
| WO-2004110974-A1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004110974-A1 | MATRIX METALLOPROTEINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160875-A1 | Matrix metalloproteinase inhibitors | MMP9, MMP20, MMP10 | MMP12 43/4885MMP13 10/4885MMP2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.